What's in a label? Radioimmunotherapy for metastatic prostate cancer

Clinical Cancer Research

Volumn 19, Issue 18, 2013, Pages 4908-4910

  Simone II, Charles B ^a   Hahn, Stephen M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; KETOCONAZOLE; MITOXANTRONE; MONOCLONAL ANTIBODY J591 LU 177; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; RADIUM CHLORIDE RA 223; SAMARIUM 153; STRONTIUM 89; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE SCINTISCANNING; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 84884540098     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1540     Document Type: Article

References (10)

1. Tagawa ST, Milowsky MI, Morris MJ, Vallabhajosula S, Christos PJ, Akhtar NH, et al. Phase II study of lutetium-177 labeled anti-prostatespecific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 2013;19:5182-91.
2. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011;59:88-95.
3. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, et al. Castration-Resistant Prostate Cancer: AUA Guideline. J Urol. 2013 May 9. [Epub ahead of print].
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
5. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
6. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13.
7. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al. Acomparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33-40.
8. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Quadramet 424Sm10/11 Study Group. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940-5.
9. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587-94.
10. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.